Baqsimi® (glukagon näspulver): Pediatrisk dos

Dosing in Children and Adolescents

NG is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.¹

The recommended dose is 3 mg glucagon administered into one nostril.¹

This is different from injectable glucagon which is dosed based on body weight in pediatric patients weighing less than 20 kg.²

The recommended dose of injectable glucagon for adults and pediatric patients weighing more than 20 kg is 1 mg given by SC, IM, or IV injection. For pediatric patients weighing less than 20 kg, the recommended dose is 0.5 mg or a dose equivalent to 20 to 30 mcg/kg.²

Pediatric Pivotal Study

A randomized, multicenter, dose finding clinical study evaluated the ability of NG 2 mg and 3 mg doses compared with injectable glucagon (0.5 mg or 1.0 mg based on body weight) administered IM to increase the BG after insulin-induced reduction in BG in children and adolescents (aged 4 to <17 years) with T1DM.³

The plasma glucose responses were similar, and adverse reactions occurred at a similar frequency and were transient with both the 2 mg and 3 mg doses of NG.³

It was determined that a single 3 mg NG dose was appropriate for use across the entire 4 to <17 year age range.³

References

1. Baqsimi [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

3. Sherr JL, Ruedy KJ, Foster NC, et al; T1D Exchange Intranasal Glucagon Investigators. Glucagon nasal powder: a promising alternative to intramuscular glucagon in youth with type 1 diabetes. Diabetes Care. 2016;39(4):555-562. https://doi.org/10.2337/dc15-1606

Glossary

BG = blood glucose

IM = intramuscular

IV = intravenous

NG = nasal glucagon (glucagon nasal powder)

SC = subcutaneous

T1DM = type 1 diabetes mellitus